RecruitingNCT06767579
Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation
Sponsor
Yonsei University
Enrollment
350 participants
Start Date
Oct 24, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective observational study that analyzes the incidence of postoperative delirium in patients undergoing liver transplantation, based on the use of the inhalational anesthetic sevoflurane and the intravenous anesthetic propofol.
Eligibility
Min Age: 19 Years
Plain Language Summary
Simplified for easier understanding
This study is comparing two types of anesthesia — sevoflurane (an inhaled anesthetic) versus propofol (an intravenous anesthetic) — to see which one causes less post-operative delirium (confusion and disorientation after surgery) in patients undergoing liver transplantation.
**You may be eligible if...**
- You are 19 years or older
- You are scheduled to undergo a liver transplant
- You will receive either sevoflurane or propofol anesthesia as part of your standard care
**You may NOT be eligible if...**
- You have hearing loss, significant cognitive impairment, or dementia
- You have a diagnosed neurological disorder such as a history of stroke, brain hemorrhage, Parkinson's disease, or other conditions affecting the brain
- You have hepatic encephalopathy (confusion related to liver failure before surgery)
- You have difficulty communicating
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06767579
Related Trials
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
NCT0676431618 locations
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785220 locations
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT0732552627 locations
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
NCT071164861 location
Y-90 Treatment Response Using Transarterial Radioembolization
NCT071458011 location